Astrazeneca (AZN) Retained Earnings (2009 - 2026)
Astrazeneca (AZN) posted quarterly Retained Earnings of $12.6 billion for Q2 2026, up 79.3% year-over-year from $7.0 billion in Q2 2025, and up 30.19% quarter-over-quarter from $9.7 billion in Q1 2026.
Astrazeneca (AZN) Retained Earnings (2009 - 2026) Analysis & Trends
Astrazeneca's Retained Earnings history runs 18 years deep, the most recent figure standing at $12.6 billion for Q2 2026.
- In Q2 2026, Retained Earnings rose 79.3% year-over-year to $12.6 billion; the TTM figure through Jun 2026 stood at $12.6 billion (up 79.3% YoY), while the FY2025 annual figure was $11.0 billion, up 247.22% from the prior year.
- Retained Earnings for Q2 2026 stood at $12.6 billion, up from $9.7 billion in the prior quarter.
- The five-year high for Retained Earnings was $12.6 billion in Q2 2026, with the low at -$2.5 billion in Q3 2022.
- The 5-year median for Retained Earnings is $1.7 billion (2023), against an average of $2.9 billion.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 212.32% in 2022, then surged 1686.79% in 2025.
- Astrazeneca's Retained Earnings stood at -$574.0 million in 2022, then soared by 361.67% to $1.5 billion in 2023, then surged by 110.39% to $3.2 billion in 2024, then surged by 247.22% to $11.0 billion in 2025, then grew by 14.76% to $12.6 billion in 2026.
- Business Quant data shows AZN's Retained Earnings at $12.6 billion in Q2 2026, $9.7 billion in Q1 2026, and $11.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.59 Bn |
| Mar 31, 2026 | 9.67 Bn |
| Dec 31, 2025 | 10.97 Bn |
| Sep 30, 2025 | 8.21 Bn |
| Jun 30, 2025 | 7.02 Bn |
| Mar 31, 2025 | 3.36 Bn |
| Dec 31, 2024 | 3.16 Bn |
| Sep 30, 2024 | 3.14 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Mar 31, 2024 | -212.00 Mn |
| Dec 31, 2023 | 1.50 Bn |
| Sep 30, 2023 | -434.00 Mn |
| Jun 30, 2023 | -234.00 Mn |
| Mar 31, 2023 | -1.83 Bn |
| Dec 31, 2022 | -574.00 Mn |
| Sep 30, 2022 | -2.47 Bn |
| Jun 30, 2022 | -1.66 Bn |
| Mar 31, 2022 | -1.23 Bn |
| Dec 31, 2021 | 1.71 Bn |
| Sep 30, 2021 | 2.20 Bn |